Eblasakimab Monthly Dosing Shows Potential for
Eblasakimab is the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile with once-monthly dosing from...
Source: globenewswire.com
Page 2 - Ericl Simpson News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Ericl Simpson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Ericl Simpson Today - Breaking & Trending Today
Eblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2b Study in Atopic Dermatitis
Eblasakimab is the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile with once-monthly dosing from initiation comparable to once every two weeks,...
Source: marketscreener.com
Dupixent® (dupilumab) Late-Breaking Data at AAD Show
More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks Nearly four times as many patients on...
Source: globenewswire.com
Press Release: Dupixent® (dupilumab) late-breaking data at
Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis ...
Source: globenewswire.com
Investegate |Sanofi - Aventis Groupe Announcements | Sanofi - Aventis Groupe: Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis
Investegate announcements from Sanofi - Aventis Groupe, Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis
Source: investegate.co.uk